Rasagiline Mesylate (Generic for Azilect)

Introducing Rasagiline Mesylate prepared to the Azilect standard—a selective MAO‑B inhibitor that slows dopaminergic neuron degeneration. This formulation improves motor function and reduces “off” periods by enhancing endogenous dopamine activity, resulting in improved movement, reduced disease progression, and enhanced quality of life.